Core Viewpoint - WuXi Biologics has entered into a license and research service agreement with Vertex Pharmaceuticals for the development of a trispecific T-cell Engager aimed at treating B-cell mediated autoimmune diseases [1][2]. Group 1: Agreement Details - Vertex Pharmaceuticals will have exclusive global rights to develop and commercialize the trispecific T-cell Engager at the preclinical stage [2]. - WuXi Biologics will receive an upfront payment and is eligible for additional milestone payments related to development, regulatory approvals, and sales, along with royalty payments [2]. Group 2: Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics from concept to commercialization [4]. - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore, and is currently supporting 945 integrated client projects, with 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [5]. Group 3: Commitment to Sustainability - WuXi Biologics emphasizes sustainability as a key component of long-term business growth, focusing on green technology innovations to provide advanced Green CRDMO solutions [6]. - The company is dedicated to achieving excellence in Environment, Social, and Governance (ESG) practices and collaborates with stakeholders to promote positive social and environmental impacts [6].

Core Insights - Sai Life Sciences Limited has completed Phase II of its new Production Block (PB-11) at its API manufacturing facility in Bidar, India, enhancing its production capabilities [1][2]. Expansion Details - Phase I of PB-11, inaugurated in December 2024, had a capacity of 110 KL, and with the addition of Phase II (~91 KL), the total capacity of PB-11 now stands at approximately 200 KL, making it the largest reactor volume block at the Bidar site [2]. - The total installed reactor capacity at the Bidar facility has increased to around 700 KL following this expansion [2][7]. Strategic Importance - The CEO of Sai Life Sciences emphasized that this expansion is not just about increasing capacity but also about providing clients with the confidence to scale operations, ensuring reliable delivery, and adapting to the complexity of their programs [3]. - The PB-11 block is designed for large-scale commercial products, reinforcing the company's commitment to high-quality API and intermediate manufacturing for regulated markets such as the US, EU, and Japan [3]. Regulatory Compliance - The Bidar facility has been inspected and approved by major global regulatory agencies, including the USFDA, PMDA (Japan), and CDSCO (India), demonstrating the company's commitment to quality and compliance [3]. - Over the past three years, Sai Life Sciences has successfully undergone more than 75 customer audits, reflecting its dedication to safety and quality standards [3]. Company Overview - Sai Life Sciences is a leading integrated CRDMO, collaborating with over 300 global pharma and biotech companies to accelerate the development of new chemical entities (NCE) [4]. - The company has a workforce of over 3,400 employees across its facilities in India, the UK, and the USA [4].